相关实验视频

Updated: May 11, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

在系统性形大细胞淋巴瘤中使用布伦图西马布静脉注射治疗方案的现实经验:一项多中心回顾性研究

Zhiqiang Zhao¹, Qinchuan Yu¹, Liping Su¹

¹Department of Hematology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China.

Frontiers in oncology

|January 22, 2025

概括

布伦图西马布维多丁 (BV) 在中国现实环境中对全身形大细胞淋巴瘤 (sALCL) 显示出高效和良好的耐受性. 这项研究证实BV是初始和后期sALCL管理的有价值的治疗选择.

科学领域:

在瘤学瘤学.
血液学血液学血液学
临床药理学临床药理学

背景情况:

在中国,系统性形大细胞淋巴瘤 (sALCL) 治疗的有效性需要在现实世界中得到验证.
布伦图西马布维多丁 (BV) 在sALCL的临床试验中显示出有前途.

研究的目的:

评估基于布伦图西马布维多丁 (BV) 的治疗方案在中国sALCL.患者中的实际有效性和安全性.
评估BV在新诊断的和耐火/复发的sALCL病例中的疗效.

主要方法:

对38名从2020年至2023年接受治疗的sALCL患者进行了回顾性多中心观察性研究.
患者接受了BV加环胺,多克索鲁比辛和普雷迪尼松 (CHP) 预先或BV后期与各种化疗方案 (GemOx,GDP,ICE) 接收.
主要终点:完全响应率 (CRR) 和整体响应率 (ORR);次要终点:无进展生存率 (PFS),整体生存率 (OS),响应持续时间 (DOR) 和不良事件 (AE).

主要成果:

观察到高整体应答率 (ORR):新诊断的患者中100%和不耐药/复发患者中70%
新诊断的完整反应率 (CRR) 为89.3%,耐药/复发患者为50%.
新诊断和耐火/复发组的两年OS率分别为100%和80%,两年PFS率分别为92.8%和70%的有利生存结果. 神经毒性是可以管理的.

结论:

布伦图西马布维多丁 (BV) 在中国实践中的sALCL治疗中显示出显著的疗效和有利的安全性.
在sALCL中,BV是第一线和后续治疗的可行选择.
完整反应后的持续疗效表明,在用BV治疗的sALCL患者中,可能会延长疾病控制.

关键词:

布伦图克西马布 (brentuximab) 是一种可见的药物.在中国,中国的中国.淋巴瘤淋巴瘤是什么现实世界的研究研究.系统性形大细胞淋巴瘤 (sALCL)

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...